Purified human polynucleotidic sequence hsCAS1, polypeptides encoded by this gene, necessary for the O-acetylation of the sialic acids and use as tools for the diagnosis and the prognosis of cancer diseases
OwnerGuilhem Janbon, Frederique Provost +1inventors
InventorsGuilhem Janbon, Frederique Provost, Francoise Dromer
Life of this patent
Estimating the term…
Abstract
A human gene, designated hsCAS1 (2880 bp), encodes for a protein with a glycosyltransferase activity on sialic acids residues. The gene and the fragment thereof, as well as the proteins and polypeptides they encodes, are useful in diagnostic compositions and as a tools for the prognostic of the evolutions of several cancers diseases. This invention is also related on the Cryptococcus neoformans gene cnCAS1 and polypeptides encoded by this polynucleotide sequence.
Claims77
A purified polynucleotide of SEQ ID NO:
- 1.
A purified polynucleotide encoding a polypeptide of SEQ ID NO:2.
A purified polynucleotide sequence derived by in vitro mutagenesis from SEQ ID NO1.
A purified polynucleotide sequence degenerate from SEQ ID NO:1 as the result of genetic code.
A nucleotidic probe comprising at least 8 amino acids of the polynucleotide sequence of SEQ ID NO:
- 1.
A nucleotidic primer comprising at least 8 amino acids of the polynucleotide sequence of SEQ ID NO:
- 1.
A primer comprising the nucleotidic sequence of SEQ ID NO:
- 5.
A primer comprising the nucleotidic sequence of SEQ ID NO:
- 6.
A primer comprising the nucleotidic sequence of SEQ ID NO:
- 7.
A primer comprising the nucleotidic sequence of SEQ ID NO:
- 8.
A primer comprising the nucleotidic sequence of SEQ ID NO:
- 9.
A primer comprising the nucleotidic sequence of SEQ ID NO:
- 10.
A plasmid pNE8 deposited at the C.N.C.M. on May 10, 2001 under the accession number I-2666.
A plasmid pPNE95 deposited at the C.N.C.M. on May 10, 2001 under the accession number I-2667.
A composition comprising at least one polypeptide encoded by hsCAS1 polynucleotide sequence.
A diagnostic method for the predictive prognosis of cancer in a patient comprising the following steps:
- a) Preparing two tissue samples, the first tissue sample being derived from an organ suspected to be tumorous and a second tissue sample being derived from a healthy patient;
- b) Optionnally making the RNA contained in the cells of the tissue sample of step a) available to hybridization;
- c) Amplifying the RNA with at least one primer according to the invention,
- d) Measuring the level of transcription of the DNA sequence corresponding to the hsCAS1 gene contained in genomic DNA of said tissue samples,
- e) Detecting the deregulation of transcription that have occured in the biosynthesis of o-Acetyltransferase in the sample derived from the patient suspected to be tumorous by comparing the resulting product of step d) derived respectively from the first and the second tissue sample.
A diagnostic method for the predictive prognosis of colorectal cancer in a patient comprising the following steps:
- a) Preparing two tissue samples from a patient, the first tissue sample being derived from an organ different than the colon and a second tissue sample being derived from the colon of said patient;
- b) Optionnally making the RNA contained in the cells of the tissue sample of step a) available to hybridization;
- c) Amplifying the RNA with at least one primer according to the invention,
- d) Measuring the level of transcription of the DNA sequence corresponding to the hsCAS1 gene contained in genomic DNA of said tissue samples,
- e) Detecting the deregulation of transcription that have occured in the biosynthesis of o-Acetyltransferase in the sample derived from the colon by comparing the resulting product of step d) derived respectively from the first and the second tissue sample.
The diagnostic method according to claim 40 or 42, wherein the measure of the level of transcription of the DNA sequence at step d) is done by the technique of quantitative RT-PCR.
A purified polynucleotide sequence of SEQ ID NO:
- 3.
A purified polynucleotide sequence encoding a polypeptide of SEQ ID NO:4.
A purified polynucleotide sequence that hybridizes to either strand of a denatured, double-stranded DNA comprising the polynucleotide of any one of claims to 44 to 48 under conditions of high stringency.
The purified polynucleotide sequence derived by in vitro mutagenesis from SEQ ID NO:3.
A purified polynucleotide sequence degenerate from SEQ ID NO:3 as the result of genetic code.
A purified polypeptide having the amino acid sequence of SEQ ID NO 4.
A nucleotidic probe comprising at least 8 amino acids of the polynucleotide sequence of SEQ ID NO:
- 3.
A nucleotidic primer comprising at least 8 amino acids of the polynucleotide sequence of SEQ ID NO:
- 3.
Purified antibodies that bind to a polypeptide according to 54.
A composition comprising at least one polypeptide encoded by cnCAS1 polynucleotide sequence.
A composition comprising at least one polynucleotide which is selected from the group consisting of a polynucleotide sequence according to 44 to 51.
A purified polynucleotide sequence comprising the SEQ ID NO:11.
Dependencies are inferred from the claim text.